MetaCap

BioAge Labs Inc. (BIOA)

NASDAQ: BIOAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

4.28-0.43 (-9.13%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BIOA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$196.67M
EPS (TTM)
-$2.56
52-week range
4.24 – 25.96
Day range
4.24 – 4.77
Volume / Avg
632.10K / 740.06K
Beta
—

52-week range

$4.24$25.96

BIOA stock today

Shares of BioAge Labs (BIOA) finished lower on Nov 20 at $4.28, a drop of 9.13% or $0.43 per share, versus the S&P 500's 3.70% decline. Shares are 83.5% below their 52-week high of $25.96, set on Jul 6, 2026 and 1.1% above the 52-week low of $4.24, near the bottom of the past year's range. BIOA is down 67.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 50.5%.

BioAge Labs has posted a net loss over the last twelve months (EPS of -$2.56), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About BioAge Labs

Company profile

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Kristen Fortney Ph.D.
Headquarters
EmeryVille, CA
Employees
60
IPO year
2024

Financial highlights

Full financials

In fiscal 2025, BioAge Labs generated $9.0 million in revenue, up 0.0% from fiscal 2024. BioAge Labs reported a net loss of $80.6 million, compared with a loss of $71.1 million a year earlier. Operating margin was -1031.5%.

BioAge Labs annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$8.99M$0—
Growth———
Net income$-80.61M$-71.11M$-63.85M
EPS (diluted)$-2.24$-6.63$-38.17

Analyst forecast

Forecast

Consensus (10 analysts)

buy

Avg. price target

$28.78+572.43%

  • Strong buy 2
  • Buy 5
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $50.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.73 vs $-0.68
Surprise
-7.35%

BIOA news

All BIOA news

BioAge Labs peers

Health Care sector
BIOA peer companies
CompanyPrice% ChgMarket capCompare
YARWYarrow Bioscience Inc.12.90-9.35%$196.53Mvs BIOA
NGENNervGen Pharma Corp.1.85-3.91%$198.55Mvs BIOA
ACIUAC Immune SA1.95-8.45%$193.88Mvs BIOA
ANTXAN2 Therapeutics Inc.5.08-2.68%$192.75Mvs BIOA
DRUGBright Minds Biosciences Inc.20.40-1.45%$201.23Mvs BIOA
BCYCBicycle Therapeutics plc ADR2.90-4.92%$203.27Mvs BIOA
FTHFaeth Therapeutics Inc.7.88-9.32%$203.65Mvs BIOA
RNACCartesian Therapeutics Inc.6.14+4.24%$187.29Mvs BIOA

Indexes, lists and sector

BioAge Labs stock FAQ

What is BioAge Labs's stock price today?

BIOA last traded at $4.28 as of Nov 20, 4:00 PM EST, down 9.13% on the day. Prices are delayed at least 15 minutes.

Who is BioAge Labs's CEO?

Dr. Kristen Fortney Ph.D. is the chief executive officer of BioAge Labs Inc., which has about 60 employees.

What is the BIOA 52-week high?

The 52-week high for BIOA is $25.96 and the 52-week low is $4.24. The stock is currently 83.5% below its high.

Compare BIOA